研究单位：[1]Beijing InnoCare Pharma Tech Co., Ltd.[2]Jiangsu Province Hospital Nanjing, Jiangsu, China[3]Shengjing Hospital of China Medical University Shenyang, Liaoning, China[4]The Fourth Hospital of Hebei Medical University Hebei, Shijiazhuang, China河北医科大学第四医院[5]Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) Tianjin, Tianjin, China[6]The First Affiliated Hospital of Zhejiang University Medical College Hangzhou, Zhejiang, China, 310000[7]Affiliated Tumor Hospital of Harbin Medical University Haerbin, Heilongjiang, China
It is a phase II, multicenter, open-label study is to evaluate the safety, efficacy and pharmacokinetics of a novel BTK inhibitor, ICP-022, in approximately 85 subjects with R/R DLBCL. There will be no control group in this study. Each subject will receive treatment orally every day in 28-day cycles. Each cycle starts immediately after the previously completed cycle without a break between cycles.
